COVAB

CovAb is a biotechnology company focused on the development of Covalent Antibodies (CovAbs), a novel class of therapeutic agents designed to form permanent chemical bonds with their targets. Unlike traditional monoclonal antibodies that bind reversibly, CovAbs provide irreversible neutralization, potentially leading to higher efficacy and longer-lasting therapeutic effects. The company's platform is currently being applied to address critical challenges in infectious diseases, such as COVID-19 and HIV, as well as neurodegenerative disorders like Alzheimer's disease. By targeting specific epitopes with high precision and permanent attachment, CovAb aims to overcome the limitations of current antibody therapies, including target dissociation and the need for frequent dosing.